TrialBMC cardiovascular disorders2014

Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials.

Helen M Colhoun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.